Home
Journals
Focus
Videos
Language
English
中文简体
Sign in
All
Title
Author
Year
Keyword
Text
Search
Journals
Engineering
1
Frontiers of Medicine
6
Selected
Sort by
select
Time desc
Time asc
Export
EndNote
RefWorks
NoteExpress
BibTe
Ref Manager
ProCite
Metabolic interventions combined with CTLA-4 and PD-1/PD-L1 blockade for the treatment of tumors: mechanisms and strategies
CTLA-4, PD-1, PD-L1, immune checkpoint blockade (ICB), metabolic reprogramming, combined tumor therapeutic strategies
Frontiers of Medicine
2023.17(5) 805-822
Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial
uveal melanoma, liver-directed therapy, immune checkpoint blockade, SIRT, anti-PD-1, anti-CTLA-4
Frontiers of Medicine
2023.17(5) 878-888
Dihydroartemisinin increased the abundance of by YAP1 depression that sensitizes hepatocellular carcinoma to anti-PD-1 immunotherapy
hepatocellular carcinoma, YAP1,
Akkermansia muciniphila
, anti-PD-1, dihydroartemisinin, bile acid
Frontiers of Medicine
2023.17(4) 729-746
High-Affinity Decoy PD-1 Mutant Screened from an Epitope-Specific Cell Library
Article
Hao Liu Chunxia Qiao Naijing Hu Zhihong Wang Jing Wang Jiannan Feng Beifen Shen Yuanfang Ma Longlong Luo
Decoy PD-1, PD-L1, Mammalian cell library, Epitope-oriented
Engineering
2021.7(11) 1557-1565
PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives
Yumeng Wang Guiling Li
PD-1,PD-L1,immune checkpoint blockade antibody,immunotherapy,cervical cancer,
Frontiers of Medicine
2019.13(4) 438-450
Activation of phagocytosis by immune checkpoint blockade
Chia-Wei Li Yun-Ju Lai Jennifer L. Hsu Mien-Chie Hung
CD47,PD-1,PD-L1,immunotherapy,TAM,phagocytosis,macrophage
Frontiers of Medicine
2018.12(4) 473-480
Molecular classification and precision therapy of cancer: immune checkpoint inhibitors
Yingyan Yu
molecular classification,precision medicine,pembrolizumab,PD-1/PD-L1,MSI-H,
Frontiers of Medicine
2018.12(2) 229-235
Prev
Next
Related search
Relevant information